Anne K. Busk

Value Strategy and Payer Engagement Director
Novo Nordisk A/S

Presentation(s):

• PB0653 - Validation of the Hemophilia Treatment Experience Measure (Hemo-TEM): a New Haemophilia-specific Patient-reported Outcome Measure

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0654 - Burden of Treatment for Adult and Adolescent People with Haemophilia (PwH): Concept Elicitation Results Supporting the Development of the Hemophilia Treatment Experience Measure (Hemo-TEM)

  Monday, July 11, 2022
  6:30 PM – 7:30 PM